Why the study?
Does Plasmonic Photothermal Therapy With Nanoparticles improve mortality, major adverse cardiovascular events, and target lesion revascularization compared to the XIENCE V stent in patients with atherosclerosis?
Does Plasmonic Photothermal Therapy With Nanoparticles improve mortality, major adverse cardiovascular events, and target lesion revascularization compared to the XIENCE V stent in patients with atherosclerosis?
In a first-in-man trial, plasmonic photothermal therapy with nanoparticles appeared safe and was associated with improved long-term clinical outcomes compared to the XIENCE V stent.
Should not change stent selection in practice; leaves open whether plasmonic photothermal therapy improves outcomes versus XIENCE V in randomized trials.
NANOM first-in-man trial demonstrates high safety with better rate of mortality, major adverse cardiovascular events and target lesion revascularization at the long-term follow-up if compare with stent XIENCE V.
No takes yet. Share an insight, caveat, or question.
Харламов et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: